Physician profile
Kerry E Hunt
NPI 1972598522
$6,655.38
in general payments reported to CMS, 2019-2025
32 companies · $857 in 2025
The $857 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $174 · 2021: $770 · 2022: $807 · 2023: $561 · 2024: $2,913 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,672 · Travel and Lodging: $652 · Education: $7.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.50 |
| Travel and Lodging | $651.75 |
| Education | $7.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,263.97 | 2019-2025 | Lensx, Clareon, Ngenuity |
| Biotissue Holdings INC. | $815.10 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $502.30 | 2023-2025 | Tecnis Simplicity, Tecnis Iol |
| Bausch & Lomb Americas INC. | $458.30 | 2022-2025 | Envista Mx60 Iol, Miebo, Envista Aspire Iol |
| Mallinckrodt Hospital Products INC. | $307.09 | 2022-2025 | Acthar |
| Oyster Point Pharma, INC. | $201.59 | 2022-2024 | Tyrvaya, Ryzumvi |
| Ivantis, INC | $166.76 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $165.66 | 2019-2021 | |
| Horizon Therapeutics Plc | $162.81 | 2021-2022 | |
| Allergan, INC. | $160.50 | 2019-2021 | |
| Ocular Therapeutix, INC. | $156.99 | 2019-2024 | Dextenza |
| Glaukos Corporation | $156.80 | 2021-2022 | |
| Rxsight INC | $137.91 | 2022 | |
| Sun Pharmaceutical Industries INC. | $125.94 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $106.43 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $104.99 | 2020-2022 | |
| Coopervision INC. | $104.95 | 2024 | Myday Contact Lens |
| Dompe US, INC. | $60.13 | 2025 | Oxervate |
| Harrow Eye, LLC | $59.79 | 2024 | Vevye |
| Rayner Intraocular Lenses Limited | $57.90 | 2024 | Omidria, Rayone Spheric, Rayone Aspheric |
| Carl Zeiss Meditec, INC. | $53.16 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $51.44 | 2024 | Purified Cortrophin Gel |
| Abbvie INC. | $41.34 | 2023-2025 | |
| Omeros Corporation | $37.82 | 2021 | |
| Aerie Pharmaceuticals, INC. | $37.72 | 2019-2021 | |
| Amgen INC. | $37.59 | 2024 | Tepezza |
| Sight Sciences, INC. | $32.52 | 2021-2022 | |
| Lensar, INC. | $20.80 | 2023 | Lensar Laser System |
| Genzyme Corporation | $20.40 | 2022 | |
| Eyepoint US, INC. | $18.85 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.95 | 2022 | |
| Notal Vision, INC. | $13.88 | 2025 | Foresee Home |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.